Eisai and SEED Therapeutics Join Forces on Molecular Glue Degraders for Neurodegeneration and Cancer
Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, and SEED Therapeutics Inc., a U.S....
Eisai
Eisai’s Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling
Eisai Co., Ltd (TYO: 4523), a prominent Japanese pharmaceutical company, has released its financial results...
EU Regulator Rejects Marketing Authorization for Biogen and Eisai’s Alzheimer’s Drug Leqembi
Biogen Inc. (NASDAQ: BIIB), a US biotechnology company, and its Japanese counterpart Eisai Co., Ltd...
Eisai Forges Partnerships with Chinese Firms to Strengthen Alzheimer’s Disease Market Presence
Eisai Co., Ltd, (TYO: 4523) a Japanese pharmaceutical company, has announced separate strategic partnerships with...
Eisai Co., Ltd Secures Asia-Pacific Rights for Fungal Drug with Sato Pharma Deal
Eisai Co., Ltd, (TYO: 4523) a leading Japanese pharmaceutical company, has entered into a strategic...
Eisai and Biogen’s Alzheimer’s Therapy Leqembi Receives Marketing Approval in Hong Kong
Eisai Co., Ltd, a Japanese pharmaceutical company, along with its co-development partner Biogen Inc. (NASDAQ:...
Eslicarbazepine Makes First Appearance in China at Sichuan University’s West China Lecheng Hospital
Eslicarbazepine, a voltage-gated sodium channel blocker, co-developed by Bial-Portela, Eisai, and Sumitomo Pharma, was first...
Eisai and Biogen Launch Alzheimer’s Drug Leqembi in China Following Market Approval
Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, in partnership with Biogen Inc. (NASDAQ:...
Eisai to Support Grassroots Healthcare in China with Significant Pariet Donation
Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced its commitment to donate 100,000...
Eisai’s Fycompa Gains New Indication for Generalized Tonic-Clonic Seizures in China
Eisai Co Ltd (TYO: 4523), a Japanese pharmaceutical company, has announced that its antiepilepsy drug...
Eisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration
Japanese pharmaceutical company Eisai (TYO: 4523) has entered into a cooperation agreement with China Resource...
FDA Reviews Eisai’s Monthly Maintenance Therapy for Early Alzheimer’s with Leqembi
Last week, the US Food and Drug Administration (FDA) announced the acceptance of an indication...
FDA Reviews Eisai’s Leqembi for Expanded Use as Monthly Alzheimer’s Therapy
The US Food and Drug Administration (FDA) has given the green light to review an...
Eli Lilly Delays Donanemab Action Date as FDA Calls for Advisory Committee Review
Eli Lilly (NYSE: LLY) has announced a delay in the action date for its Alzheimer’s...
Biogen Discontinues Aduhelm Development, Redirects Focus to Other Alzheimer’s Therapies
Biogen (NASDAQ: BIIB) has announced its decision to discontinue the development and commercialization of its...
Eisai’s Alzheimer’s Drug Leqembi Earns Marketing Approval in China
Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced that it has received marketing...
Eisai and Medivir’s Combo Therapy Advances in Liver Cancer with Positive Trial Results
Japanese pharmaceutical company Eisai’s (TYO: 4523) kinase inhibitor Lenvima (Lenvatinib), combined with Swedish partner Medivir’s...
SciClone’s Partner Menarini Files for Elacestrant Approval in Macau for Advanced Breast Cancer
SciClone Pharmaceuticals Inc. (HKG: 6600) has announced that its Italian partner, Menarini Group, has submitted...
Eisai’s Lemborexant Sleep Aid Lemborexant Filed for NMPA Approval in China
The China Center for Drug Evaluation (CDE) website has indicated that Japan-based Eisai (TYO: 4523)...
Eisai and BioArctic Set December Launch for Alzheimer’s Drug Leqembi in Japan
Eisai (TYO: 4523) and BioArctic (STO: BIOA-B) have announced the launch of Leqembi (lecanemab) in...